Clynav

RSS

Salmon pancreas disease vaccine (recombinant DNA plasmid)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Clynav. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Clynav.

For practical information about using Clynav, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 05/03/2019

Authorisation details

Product details
Name
Clynav
Agency product number
EMEA/V/C/002390
Active substance
pUK-SPDV-poly2#1 DNA plasmid coding for salmon pancreas disease virus proteins
International non-proprietary name (INN) or common name
Salmon pancreas disease vaccine (recombinant DNA plasmid)
Species
Atlantic salmon
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI10AX
Publication details
Marketing-authorisation holder
Elanco GmbH
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
26/06/2017
Contact address

Heinz-Lohmann-Str 4
27472 Cuxhaven
Germany

Product information

26/02/2019 Clynav - EMEA/V/C/002390 - IA-0006

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for Atlantic salmon

Therapeutic indication

For the active immunisation of Atlantic salmon to reduce impaired daily weight gain, and reduce mortality, and cardiac, pancreatic and skeletal muscle lesions caused by pancreas disease following infection with salmonid alphavirus subtype 3 (SAV3).

Assessment history

How useful was this page?

Add your rating
Average
6 ratings
1 rating
3 ratings
1 rating